Published in Front Oncol on March 04, 2013
WW domain-containing oxidoreductase in neuronal injury and neurological diseases. Oncotarget (2014) 0.96
Emerging biomarkers in glioblastoma. Cancers (Basel) (2013) 0.96
Introduction to a thematic issue for WWOX. Exp Biol Med (Maywood) (2015) 0.81
Alteration of WWOX in human cancer: a clinical view. Exp Biol Med (Maywood) (2015) 0.80
The role of p53 in cancer drug resistance and targeted chemotherapy. Oncotarget (2016) 0.79
Role of WWOX and NF-κB in lung cancer progression. Transl Respir Med (2013) 0.79
Mechanistic Nanotherapeutic Approach Based on siRNA-Mediated DJ-1 Protein Suppression for Platinum-Resistant Ovarian Cancer. Mol Pharm (2016) 0.76
BACH1 Promotes Temozolomide Resistance in Glioblastoma through Antagonizing the Function of p53. Sci Rep (2016) 0.75
Predicting the cell death responsiveness and sensitization of glioma cells to TRAIL and temozolomide. Oncotarget (2016) 0.75
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol (2009) 25.96
A restricted cell population propagates glioblastoma growth after chemotherapy. Nature (2012) 8.88
p53 isoforms can regulate p53 transcriptional activity. Genes Dev (2005) 6.76
Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol (2008) 4.32
The expanding universe of p53 targets. Nat Rev Cancer (2009) 3.49
Possible future issues in the treatment of glioblastomas: special emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis. J Clin Oncol (2005) 3.46
Temozolomide and treatment of malignant glioma. Clin Cancer Res (2000) 2.95
Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine. Oncogene (2006) 2.82
p53 Research: the past thirty years and the next thirty years. Cold Spring Harb Perspect Biol (2010) 2.34
Hyaluronidase induction of a WW domain-containing oxidoreductase that enhances tumor necrosis factor cytotoxicity. J Biol Chem (2000) 2.20
Regulation of human p53 activity and cell localization by alternative splicing. Mol Cell Biol (2004) 2.01
Mechanisms of chemoresistance to alkylating agents in malignant glioma. Clin Cancer Res (2008) 1.94
Concern WWOX gene restoration prevents lung cancer growth in vitro and in vivo. Proc Natl Acad Sci U S A (2005) 1.84
Temozolomide: mechanisms of action, repair and resistance. Curr Mol Pharmacol (2012) 1.82
p53 effects both the duration of G2/M arrest and the fate of temozolomide-treated human glioblastoma cells. Cancer Res (2001) 1.80
Loss of ATM/Chk2/p53 pathway components accelerates tumor development and contributes to radiation resistance in gliomas. Cancer Cell (2010) 1.68
O6-methylguanine-DNA methyltransferase expression strongly correlates with outcome in childhood malignant gliomas: results from the CCG-945 Cohort. J Clin Oncol (2006) 1.66
Two internal ribosome entry sites mediate the translation of p53 isoforms. EMBO Rep (2006) 1.64
Chemoresistance of glioblastoma cancer stem cells--much more complex than expected. Mol Cancer (2011) 1.64
p53 and its isoforms in cancer. Br J Cancer (2007) 1.62
MiR-21 protected human glioblastoma U87MG cells from chemotherapeutic drug temozolomide induced apoptosis by decreasing Bax/Bcl-2 ratio and caspase-3 activity. Brain Res (2010) 1.56
Loss of WWOX expression in gastric carcinoma. Clin Cancer Res (2004) 1.55
The fragile genes FHIT and WWOX are inactivated coordinately in invasive breast carcinoma. Cancer (2004) 1.49
The tumor suppressor gene WWOX at FRA16D is involved in pancreatic carcinogenesis. Clin Cancer Res (2004) 1.45
WW domain-containing oxidoreductase: a candidate tumor suppressor. Trends Mol Med (2006) 1.44
The pan-Bcl-2 inhibitor (-)-gossypol triggers autophagic cell death in malignant glioma. Mol Cancer Res (2010) 1.41
WOX1 is essential for tumor necrosis factor-, UV light-, staurosporine-, and p53-mediated cell death, and its tyrosine 33-phosphorylated form binds and stabilizes serine 46-phosphorylated p53. J Biol Chem (2005) 1.40
DNA damage induced by temozolomide signals to both ATM and ATR: role of the mismatch repair system. Mol Pharmacol (2004) 1.40
Association of Wwox with ErbB4 in breast cancer. Cancer Res (2007) 1.37
p53 directly transactivates Δ133p53α, regulating cell fate outcome in response to DNA damage. Cell Death Differ (2010) 1.36
Drug resistance in glioblastoma: a mini review. Neurochem Res (2012) 1.36
Engagement of CD44 promotes Rac activation and CD44 cleavage during tumor cell migration. J Biol Chem (2003) 1.34
Transforming growth factor beta1 signaling via interaction with cell surface Hyal-2 and recruitment of WWOX/WOX1. J Biol Chem (2009) 1.28
Alkylpurine-DNA-N-glycosylase confers resistance to temozolomide in xenograft models of glioblastoma multiforme and is associated with poor survival in patients. J Clin Invest (2011) 1.27
Zfra affects TNF-mediated cell death by interacting with death domain protein TRADD and negatively regulates the activation of NF-kappaB, JNK1, p53 and WOX1 during stress response. BMC Mol Biol (2007) 1.26
WWOX gene expression abolishes ovarian cancer tumorigenicity in vivo and decreases attachment to fibronectin via integrin alpha3. Cancer Res (2009) 1.25
Survival and death strategies in glioma cells: autophagy, senescence and apoptosis triggered by a single type of temozolomide-induced DNA damage. PLoS One (2013) 1.24
O(6)-methylguanine-DNA methyltransferase in glioma therapy: promise and problems. Biochim Biophys Acta (2012) 1.22
Inhibition of DNA repair for sensitizing resistant glioma cells to temozolomide. J Neurosurg (2003) 1.20
Mismatch repair proteins as sensors of alkylation DNA damage. Cancer Cell (2006) 1.20
Signaling from membrane receptors to tumor suppressor WW domain-containing oxidoreductase. Exp Biol Med (Maywood) (2010) 1.19
17beta-Estradiol upregulates and activates WOX1/WWOXv1 and WOX2/WWOXv2 in vitro: potential role in cancerous progression of breast and prostate to a premetastatic state in vivo. Oncogene (2005) 1.18
Inhibition of the Wnt/beta-catenin pathway by the WWOX tumor suppressor protein. Oncogene (2009) 1.15
p53 down-regulates human matrix metalloproteinase-1 (Collagenase-1) gene expression. J Biol Chem (1999) 1.15
Molecular mechanisms of temozolomide resistance in glioblastoma multiforme. Expert Rev Anticancer Ther (2012) 1.15
Overcoming temozolomide resistance in glioblastoma via dual inhibition of NAD+ biosynthesis and base excision repair. Cancer Res (2011) 1.15
WOX1 is essential for UVB irradiation-induced apoptosis and down-regulated via translational blockade in UVB-induced cutaneous squamous cell carcinoma in vivo. Clin Cancer Res (2005) 1.14
PKA-mediated protein phosphorylation regulates ezrin-WWOX interaction. Biochem Biophys Res Commun (2006) 1.14
Acquisition of chemoresistance in gliomas is associated with increased mitochondrial coupling and decreased ROS production. PLoS One (2011) 1.14
Inhibition of histone deacetylation potentiates the evolution of acquired temozolomide resistance linked to MGMT upregulation in glioblastoma xenografts. Clin Cancer Res (2012) 1.13
Anti-glioma therapy with temozolomide and status of the DNA-repair gene MGMT. Anticancer Res (2009) 1.12
WW domain-containing proteins: retrospectives and the future. Front Biosci (Landmark Ed) (2012) 1.11
Molecular mechanisms underlying WOX1 activation during apoptotic and stress responses. Biochem Pharmacol (2003) 1.11
STAT3 inhibition overcomes temozolomide resistance in glioblastoma by downregulating MGMT expression. Mol Cancer Ther (2012) 1.10
Integrin α5β1 plays a critical role in resistance to temozolomide by interfering with the p53 pathway in high-grade glioma. Cancer Res (2012) 1.09
Distinct molecular mechanisms of acquired resistance to temozolomide in glioblastoma cells. J Neurochem (2012) 1.09
Effect of aberrant p53 function on temozolomide sensitivity of glioma cell lines and brain tumor initiating cells from glioblastoma. J Neurooncol (2010) 1.09
The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models. Br J Cancer (2012) 1.09
WWOX expression in different histologic types and subtypes of non-small cell lung cancer. Clin Cancer Res (2007) 1.06
Use of wild-type p53 to achieve complete treatment sensitization of tumor cells expressing endogenous mutant p53. Mol Carcinog (1995) 1.05
Complement C1q activates tumor suppressor WWOX to induce apoptosis in prostate cancer cells. PLoS One (2009) 1.05
CD44 in human glioma correlates with histopathological grade and cell migration. Pathol Int (2012) 1.04
Role of the WWOX tumor suppressor gene in bone homeostasis and the pathogenesis of osteosarcoma. Am J Cancer Res (2011) 1.03
Human smooth muscle alpha-actin gene is a transcriptional target of the p53 tumor suppressor protein. Oncogene (1998) 1.00
Fulfilling the metabolic requirements for cell proliferation. Biochem J (2012) 1.00
Role of the WWOX gene, encompassing fragile region FRA16D, in suppression of pancreatic carcinoma cells. Cancer Sci (2008) 1.00
Dramatic co-activation of WWOX/WOX1 with CREB and NF-kappaB in delayed loss of small dorsal root ganglion neurons upon sciatic nerve transection in rats. PLoS One (2009) 0.98
Drosophila orthologue of WWOX, the chromosomal fragile site FRA16D tumour suppressor gene, functions in aerobic metabolism and regulates reactive oxygen species. Hum Mol Genet (2010) 0.98
WWOX-mediated apoptosis in A549 cells mainly involves the mitochondrial pathway. Mol Med Rep (2012) 0.96
Resveratrol reverses temozolomide resistance by downregulation of MGMT in T98G glioblastoma cells by the NF-κB-dependent pathway. Oncol Rep (2012) 0.96
Identification of an In Vivo MEK/WOX1 Complex as a Master Switch for Apoptosis in T Cell Leukemia. Genes Cancer (2011) 0.96
Standard therapy for glioblastoma--a review of where we are. Neurol Med Chir (Tokyo) (2010) 0.94
MicroRNA-21: a ubiquitously expressed pro-survival factor in cancer and other diseases. Mol Cell Biochem (2011) 0.93
Alterations of common chromosome fragile sites in hematopoietic malignancies. Int J Hematol (2004) 0.93
Hyaluronidase is more elevated in human brain metastases than in primary brain tumours. Anticancer Res (2002) 0.91
O6-Methylguanine-methyltransferase (MGMT) promoter methylation status in glioma stem-like cells is correlated to temozolomide sensitivity under differentiation-promoting conditions. Int J Mol Sci (2012) 0.91
A complete compilation of matrix metalloproteinase expression in human malignant gliomas. World J Clin Oncol (2012) 0.89
Molecular analysis of WWOX expression correlation with proliferation and apoptosis in glioblastoma multiforme. J Neurooncol (2010) 0.89
TIAF1 self-aggregation in peritumor capsule formation, spontaneous activation of SMAD-responsive promoter in p53-deficient environment, and cell death. Cell Death Dis (2012) 0.88
WWOX induces apoptosis and inhibits proliferation of human hepatoma cell line SMMC-7721. World J Gastroenterol (2012) 0.87
Expression and regulation patterns of hyaluronidases in small cell lung cancer and glioma lines. Oncol Rep (2003) 0.87
Hyperoxia resensitizes chemoresistant human glioblastoma cells to temozolomide. J Neurooncol (2012) 0.86
Overexpression of WW domain-containing oxidoreductase WOX1 preferentially induces apoptosis in human glioblastoma cells harboring mutant p53. Biomed Pharmacother (2012) 0.85
The identification of a novel gene, MAPO2, that is involved in the induction of apoptosis triggered by O⁶-methylguanine. PLoS One (2012) 0.83
The strategy for enhancing temozolomide against malignant glioma. Front Oncol (2012) 0.83
CD133: holy of grail of neuro-oncology or promiscuous red-herring? Cell Prolif (2012) 0.79
Down-regulation of WW domain-containing oxidoreductase induces Tau phosphorylation in vitro. A potential role in Alzheimer's disease. J Biol Chem (2004) 1.31
Transforming growth factor beta1 signaling via interaction with cell surface Hyal-2 and recruitment of WWOX/WOX1. J Biol Chem (2009) 1.28
Zfra affects TNF-mediated cell death by interacting with death domain protein TRADD and negatively regulates the activation of NF-kappaB, JNK1, p53 and WOX1 during stress response. BMC Mol Biol (2007) 1.26
Signaling from membrane receptors to tumor suppressor WW domain-containing oxidoreductase. Exp Biol Med (Maywood) (2010) 1.19
17beta-Estradiol upregulates and activates WOX1/WWOXv1 and WOX2/WWOXv2 in vitro: potential role in cancerous progression of breast and prostate to a premetastatic state in vivo. Oncogene (2005) 1.18
Downregulation of CREB expression in Alzheimer's brain and in Aβ-treated rat hippocampal neurons. Mol Neurodegener (2011) 1.14
WOX1 is essential for UVB irradiation-induced apoptosis and down-regulated via translational blockade in UVB-induced cutaneous squamous cell carcinoma in vivo. Clin Cancer Res (2005) 1.14
MPP+-induced neuronal death in rats involves tyrosine 33 phosphorylation of WW domain-containing oxidoreductase WOX1. Eur J Neurosci (2008) 1.08
Spatiotemporal focusing-based widefield multiphoton microscopy for fast optical sectioning. Opt Express (2012) 1.07
Subconjunctival mitomycin C before pterygium excision: an ultrastructural study. Cornea (2008) 1.05
Complement C1q activates tumor suppressor WWOX to induce apoptosis in prostate cancer cells. PLoS One (2009) 1.05
Dramatic co-activation of WWOX/WOX1 with CREB and NF-kappaB in delayed loss of small dorsal root ganglion neurons upon sciatic nerve transection in rats. PLoS One (2009) 0.98
Zfra is an inhibitor of Bcl-2 expression and cytochrome c release from the mitochondria. Cell Signal (2008) 0.98
Zfra is a small wizard in the mitochondrial apoptosis. Aging (Albany NY) (2010) 0.97
Identification of an In Vivo MEK/WOX1 Complex as a Master Switch for Apoptosis in T Cell Leukemia. Genes Cancer (2011) 0.96
N-methyl-D-aspartate receptor subunit NR2A and NR2B messenger RNA levels are altered in the hippocampus and entorhinal cortex in Alzheimer's disease. J Neurol Sci (2002) 0.94
Glioma cell integrin expression and their interactions with integrin antagonists: Research Article. Cancer Ther (2005) 0.93
Cloning and characterization of a small-size peptide Zfra that regulates the cytotoxic function of tumor necrosis factor by interacting with JNK1. Biochem Biophys Res Commun (2005) 0.90
TIAF1 participates in the transforming growth factor beta1--mediated growth regulation. Ann N Y Acad Sci (2003) 0.88
TIAF1 and p53 functionally interact in mediating apoptosis and silencing of TIAF1 abolishes nuclear translocation of serine 15-phosphorylated p53. DNA Cell Biol (2004) 0.88
Prc contributes to Escherichia coli evasion of classical complement-mediated serum killing. Infect Immun (2012) 0.87
WWOX suppresses prostate cancer cell progression through cyclin D1-mediated cell cycle arrest in the G1 phase. Cell Cycle (2015) 0.87
High expression of TIAF-1 in chronic kidney and liver allograft rejection and in activated T-helper cells. Transplantation (2003) 0.87
Silent corticotroph adenomas: further clinical and pathological observations. Hum Pathol (2004) 0.85
Overexpression of WW domain-containing oxidoreductase WOX1 preferentially induces apoptosis in human glioblastoma cells harboring mutant p53. Biomed Pharmacother (2012) 0.85
Assessing current therapeutic approaches to decode potential resistance mechanisms in glioblastomas. Front Oncol (2013) 0.85
Visfatin induces stromal cell-derived factor-1 expression by β1 integrin signaling in colorectal cancer cells. J Cell Physiol (2013) 0.84
High-throughput fabrication of gray-level biomicrostructures via temporal focusing excitation and laser pulse control. J Biomed Opt (2013) 0.84
Vitamin D receptor 1a promotor -1521 G/C and -1012 A/G polymorphisms in polycystic ovary syndrome. Taiwan J Obstet Gynecol (2012) 0.84
Solanum incanum extract (SR-T100) induces human cutaneous squamous cell carcinoma apoptosis through modulating tumor necrosis factor receptor signaling pathway. J Dermatol Sci (2011) 0.82
Surface plasmon-enhanced two-photon fluorescence microscopy for live cell membrane imaging. Opt Express (2009) 0.81
Study of cell-biosubstrate contacts via surface plasmon polariton phase microscopy. Opt Express (2010) 0.81
The inhibitory effect of CIL-102 on the growth of human astrocytoma cells is mediated by the generation of reactive oxygen species and induction of ERK1/2 MAPK. Toxicol Appl Pharmacol (2012) 0.80
WW domain-containing oxidoreductase is involved in upregulation of matrix metalloproteinase 9 by Epstein-Barr virus latent membrane protein 2A. Biochem Biophys Res Commun (2013) 0.80
Experimental intrauterine infection with Prevotella bivia in New Zealand White rabbits. Am J Obstet Gynecol (2004) 0.79
Role of WWOX/WOX1 in Alzheimer's disease pathology and in cell death signaling. Front Biosci (Elite Ed) (2012) 0.79
Conformationally altered hyaluronan restricts complement classical pathway activation by binding to C1q, C1r, C1s, C2, C5 and C9, and suppresses WOX1 expression in prostate DU145 cells. Int J Mol Med (2007) 0.79
Chronic intrauterine and fetal infection with Gardnerella vaginalis. Am J Obstet Gynecol (2002) 0.78
Role of WWOX/WOX1 in Alzheimer's disease pathology and in cell death signaling. Front Biosci (Schol Ed) (2013) 0.78
Quantitative proteomic analysis of the inhibitory effects of CIL-102 on viability and invasiveness in human glioma cells. Toxicol Appl Pharmacol (2013) 0.78
Spontaneously ruptured subcapsular liver hematoma associated with hemolysis, elevated liver enzymes and low platelets (HELLP) syndrome. Taiwan J Obstet Gynecol (2010) 0.77
Investigation of two-photon excited fluorescence increment via crosslinked bovine serum albumin. Opt Express (2012) 0.77
Delayed granulocyte colony-stimulating factor treatment promotes functional recovery in rats with severe contusive spinal cord injury. Spine (Phila Pa 1976) (2012) 0.77
Imaging live cell membranes via surface plasmon-enhanced fluorescence and phase microscopy. Opt Express (2010) 0.76
Malignant sweat gland tumor presenting as an unusual dural-based lesion: case report. J Neurooncol (2010) 0.75
Evidence for the Inhibition by Temozolomide, an Imidazotetrazine Family Alkylator, of Intermediate-Conductance Ca2+-Activated K+ Channels in Glioma Cells. Cell Physiol Biochem (2016) 0.75
Complex chromosome rearrangement 46,XY, der(9)t(Y;9)(q12;p23) in a girl with sex reversal and mental retardation. Urology (2010) 0.75
Cell line studies of glioblastoma and malignant glioma using a newly discovered prenylated chalcone. Pharm Biol (2011) 0.75